Skip to main content

Table 3 Incidence of adverse reactions to cluster immunotherapy during the build-up phase and first year of the maintenance phase

From: Observational study on the tolerability of cluster subcutaneous immunotherapy in patients with rhinoconjunctivitis with or without asthma sensitized to pollen: the SIMO study

Reference

Adverse reactions by number of patients at risk (adverse reactions/number of patients) %

Adverse reactions by number of AIT injections (adverse reactions/number of injections*) %

Local reactions

Systemic reactions

Local reactions

Systemic reactions

Solá, 2018

(60/110) 54.5 (95% CI 44.8–64)

(9/110) 8.2 (95% CI 3.8–15)

(60/110*(6 + 12)) 3.03 (95% CI 2.3–3.9)

(9/110*(6 + 12)) 0.46 (95% CI 0.2–0.9)

Walker, 2001 [7]

(0/22) 0

(4/22) 18.2

(0/22*(11 + 11)) 0

(4/22*(11 + 11)) 0.8

Crimi, 2004 [9]

(3/15) 20

(0/15) 0

(3/15*(12 + 10)) 0.9

(0/15*(12 + 10)) 0

Nanda, 2004 [10]

(0/20) 0

(1/20) 5

(0/20*(9 + 11)) 0

(1/20*(9 + 11)) 0.3

Tabar, 2005 [11]

(7/120) 5.8

(4/120) 3.3

(7/120*(16 + 11)) 0.2

(4/120*(16 + 11)) 0.1

Colás, 2006 [13]

(16/41) 39

(16/41) 39

(16/41*(7 + 12)) 2.1

(16/41*(7 + 12)) 2.1

Subiza, 2008 [14]

(7/22) 31.8

(0/22) 0

(7/22*(5 + 12)) 1.9

(0/22*(5 + 12)) 0

Zhang, 2009 [16]

(18/45) 40

(5/45) 11.1

(18/45*(14 + 11)) 1.6

(5/45*(14 + 11)) 0.4

Lou, 2012 [17]

Klimek, 2014 [18]

(7/61) 11.5

(5/61) 8.2

(7/61*(5 + 11)) 0.7

(5/61*(5 + 11)) 0.5

González-Gutiérrez, 2012 [6]

(32/127) 25.2

(14/127) 11

(32/127*(7 + 11)) 1.4

(14/127*(7 + 11)) 0.6

(26/177) 14.7

(20/177) 11.3

(26/177*(5 + 11)) 0.9

(20/177*(5 + 11)) 0.7

  1. *Number of AIT injections calculated as number of patients multiplied by number of injections in the build-up phase plus number of injections in the first year of the maintenance phase